NEW DELHI: The government on Monday said it identified 26 potential cases of bleeding and blood clotting in India due to the administration of the AstraZeneca vaccine in India.
Serum Institute of India is producing Covishield vaccine in India in partnership with AstraZeneca.
As per a report submitted by the National AEFI (Adverse Event Following Immunization) Committee to the Ministry of Health & Family Welfare, “more than 23,000 adverse events were reported” through the CO-WIN platform reported from 684 of the 753 districts of the country.
“Of these, only 700 cases (@ 9.3 cases /million doses administered) were reported to be serious and severe nature” the report said.
“26 cases have been reported to be potential thromboembolic (formation of a clot in a blood vessel that might also break loose and carried by the blood stream to plug another vessel) events – following the administration of Covishield vaccine – with a reporting rate of 0.61 cases/ million doses,” said the committee.
The committee also said no potential thromboembolic events were reported following administration of Covaxin vaccine.
The health ministry separately issued advisories to healthcare workers and vaccine beneficiaries to encourage people to be aware of suspected thromboembolic symptoms.
These include breathlessness; pain in chest; pain in limbs/pain on pressing limbs or swelling in limbs (arm or calf);
multiple, pinhead size red spots or bruising of skin in an area beyond the injection site; persistent abdominal pain with or without vomiting; seizures in the absence of previous history of seizures with or without vomiting;
severe and persistent headache with or without vomiting (in the absence of previous history of migraine or chronic headache); weakness/paralysis of limbs or any particular side or part of the body (including face); persistent vomiting without any obvious reason; blurred vision or pain in eyes or having double vision and change in mental status or having confusion or depressed level of consciousness.